Therapy News and Research

RSS

Fear hard to extinguish from the teenage brain

A new study by Weill Cornell Medical College researchers shows that adolescents' reactions to threat remain high even when the danger is no longer present. According to researchers, once a teenager's brain is triggered by a threat, the ability to suppress an emotional response to the threat is diminished which may explain the peak in anxiety and stress-related disorders during this developmental period.

28 Sep 2012

Conditionally reprogrammed cells help identify effective therapy for HPV-positive RRP

Using a newly discovered cell technology, Georgetown University Medical Center researchers were able to identify an effective therapy for a patient with a rare type of lung tumor. The single case study, reported in the September 27 issue of New England Journal of Medicine, provides a snapshot of the new technology's promising potential; however, researchers strongly caution that it could be years before validation studies are completed and regulatory approval received for its broader use.

28 Sep 2012

Researchers solve key part of muscle regeneration mystery

Working with mice, Johns Hopkins researchers have solved a key part of a muscle regeneration mystery plaguing scientists for years, adding strong support to the theory that muscle mass can be built without a complete, fully functional supply of muscle stem cells.

28 Sep 2012

Boston Scientific receives CE MARK approval for Vercise DBS to treat Parkinson's

Boston Scientific Corporation received CE Mark approval for use of its Vercise Deep Brain Stimulation (DBS) System for the treatment of Parkinson's disease.

28 Sep 2012

Incarcerated patients with chronic HCV likely to achieve sustained viral response

Incarcerated patients with chronic hepatitis C virus (HCV) infection are just as likely to respond to treatment for the disease as patients in the community, according to findings published in the October issue of Hepatology, a peer-reviewed journal of the American Association for the Study of Liver Diseases.

28 Sep 2012

Japanese MHLW approves Sosei’s Seebri inhalation capsules to treat COPD

Sosei Group Corporation confirms the information released today by Novartis that the Japanese Ministry of Health, Labor and Welfare (MHLW) has approved Seebri (glycopyrronium bromide) Inhalation Capsules 50 mcg administered through the Breezhaler device, as a once-daily, long-term, inhaled maintenance bronchodilator treatment for the relief of various symptoms due to airway obstructive disease in chronic obstructive pulmonary disease.

28 Sep 2012

Two-part ACR guidelines on gout

Gout is one of the most common forms of inflammatory arthritis, affecting nearly 4% of adult Americans. Newly approved guidelines that educate patients in effective methods to prevent gout attacks and provide physicians with recommended therapies for long-term management of this painful disease are published in Arthritis Care & Research, a peer-reviewed journal of the American College of Rheumatology (ACR).

28 Sep 2012

ARIAD Pharmaceuticals completes rolling submission of ponatinib NDA with FDA

ARIAD Pharmaceuticals, Inc. today announced it has completed the rolling submission of the New Drug Application (NDA) for its investigational BCR-ABL inhibitor, ponatinib, to the U.S. Food and Drug Administration (FDA).

28 Sep 2012

Life Technologies receives FDA clearance for OpTmizer CTS T-cell expansion media

Life Technologies Corporation today announced it has received FDA 510(k) clearance for its OpTmizer CTS T-Cell Expansion Tissue Culture Medium – a reagent that is now cleared as a Class II medical device and offers cost- and time-saving advantages for transitioning studies from the research bench to clinical trials.

28 Sep 2012

Bayer HealthCare receives FDA approval for Stivarga to treat colorectal cancer

The U.S. Food and Drug Administration today approved Stivarga (regorafenib) to treat patients with colorectal cancer that has progressed after treatment and spread to other parts of the body (metastatic).

28 Sep 2012

Early, intensive therapy with adalimumab can help treat rheumatoid arthritis

Early, intensive therapy with a biotechnologically produced medication can provide significantly faster pain relief for patients with rheumatic joint inflammation. Damage to joints can also be reduced when the medication is applied right at the beginning of the illness.

27 Sep 2012

Key bacterial protein structures reveal one of the biochemical secrets behind multi-drug tolerance

The structures of key bacterial proteins have revealed one of the biochemical secrets that enables bacteria to outwit antibiotics.

27 Sep 2012

Novel oral anticoagulant bleeding risk offsets clinical benefit

The use of orally activated Xa antagonist and direct thrombin inhibitors is associated with a significant increase in major bleeding events in acute coronary syndrome patients, a study shows.

27 Sep 2012

Obesity affects taste in children, adolescents

Study results show that obese children perceive taste differently from their healthy weight peers, being significantly less able to identify the individual tastes of salty, umami, and bitter.

27 Sep 2012

Warfarin therapy should not be stopped completely after GI bleeding

The decision to not resume warfarin therapy following a gastrointestinal bleeding event is linked to an increased risk for thrombosis and mortality, researchers suggest.

27 Sep 2012

GW to evaluate effectiveness of glucose-lowering drugs against type 2 diabetes

John Lachin, professor of biostatistics, epidemiology and statistics at the George Washington University, has been awarded a five-year, $134 million grant from the National Institute of Health's National Institute of Diabetes and Digestive and Kidney Diseases to conduct a clinical trial examining the long-term effectiveness of several glucose-lowering medications for treatment of people with type 2 diabetes. The grant sets a record as the largest sum award GW has ever received.

27 Sep 2012

Scientists discover 12 genetic markers for ED in prostate cancer patients after radiotherapy

In the first study of its kind, a research team led by Mount Sinai School of Medicine and Albert Einstein College of Medicine of Yeshiva University discovered 12 genetic markers associated with the development of erectile dysfunction (ED) in prostate cancer patients who were treated with radiation.

27 Sep 2012

Pfizer, Bristol-Myers Squibb report FDA acknowledgement of ELIQUIS NDA resubmission

Bristol-Myers Squibb Company and Pfizer Inc. today announced that the U.S. Food and Drug Administration (FDA) has acknowledged receipt of the New Drug Application (NDA) resubmission for ELIQUIS (apixaban) to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation (NVAF).

27 Sep 2012

Karolinska Institutet scientists discover new approach to treat type II diabetes

An international team of scientists, led from Karolinska Institutet in Sweden, have discovered an entirely new approach to the treatment of type II diabetes. The therapy involves the blockade of signalling by a protein known as VEGF-B and this prevents fat from accumulating in the 'wrong' places, such as in muscles and in the heart. As a result the cells within these tissues are once again able to respond to insulin.

27 Sep 2012

Loyola now offers sacral nerve stimulation for patients with fecal incontinence

Fecal incontinence, or the inability to control the bowels, is a highly underreported and stigmatized condition, according to colorectal surgeons at Loyola University Health System (LUHS).

27 Sep 2012

Therapy News and Research

Fear hard to extinguish from the teenage brain

Conditionally reprogrammed cells help identify effective therapy for HPV-positive RRP

Researchers solve key part of muscle regeneration mystery

Boston Scientific receives CE MARK approval for Vercise DBS to treat Parkinson's

Incarcerated patients with chronic HCV likely to achieve sustained viral response

Japanese MHLW approves Sosei’s Seebri inhalation capsules to treat COPD

Two-part ACR guidelines on gout

ARIAD Pharmaceuticals completes rolling submission of ponatinib NDA with FDA

Life Technologies receives FDA clearance for OpTmizer CTS T-cell expansion media

Bayer HealthCare receives FDA approval for Stivarga to treat colorectal cancer

Early, intensive therapy with adalimumab can help treat rheumatoid arthritis

Key bacterial protein structures reveal one of the biochemical secrets behind multi-drug tolerance

Novel oral anticoagulant bleeding risk offsets clinical benefit

Obesity affects taste in children, adolescents

Warfarin therapy should not be stopped completely after GI bleeding

GW to evaluate effectiveness of glucose-lowering drugs against type 2 diabetes

Scientists discover 12 genetic markers for ED in prostate cancer patients after radiotherapy

Pfizer, Bristol-Myers Squibb report FDA acknowledgement of ELIQUIS NDA resubmission

Karolinska Institutet scientists discover new approach to treat type II diabetes

Loyola now offers sacral nerve stimulation for patients with fecal incontinence

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News